Former pharmaceutical industry executives with a unique combination of experience in large, mid-sized, and small pharmaceutical and biotechnology companies announce today the launch of BioEndpoint Consulting. The firm was created to help small and mid-sized companies navigate the complexities of the pharmaceutical product development and commercialization processes.
More on Press Releases

    Kuoni Scores Joint Top Place In The Recent Which? Survey
    Titan Poker Launches Online Poker Promotion For Irish Winter Festival
    China Group-Buying Statistics Report For May 2011: Meituan.com Ranks First In Terms Of Overall Strength
    Holidaying Brits Risk Hefty Medical Bills By Travelling Without An EHIC
    Advantest Completes Acquisition Of Verigy Shares
    Science News Prime Now Available For Subscription
    Commonwealth Law Ministers To Hold Triennial Meeting In Australia
    Arab Spring May Bring Unseasonal Cheer To London Property Market, But Do Fools Rush In?
    Intersolar North America - Kioto And GREENoneTEC Present Brand New Solar Energy Solutions For The US Market
    Greenland Group Announces Construction Plans For The World's Third Tallest Building, Located In Wuhan, China

“The pharmaceutical industry as a whole has a special set of challenges ranging from losses in patent protection, to toughening regulatory hurdles, and stricter cost controls,” said Jeff Sherman, co-Managing Partner, BioEndpoint Consulting. “These pressures, combined with the intensifying struggle to differentiate products from market competitors, have put a vice grip on commercialization teams with smaller budgets and larger workloads.” BioEndpoint Consulting was created to serve as an organic extension of the small and mid-sized biotechnology, pharmaceutical, and medical device companies’ core commercial team. However, unlike traditional consulting firms, BioEndpoint provides partnerships with seasoned industry professionals who have taken on the same and similar specialized challenges time and again.

“Our consulting model pairs the commercial team with support from consultant team mates who have actual operating experience,” said James Garrison, co-Managing Partner, BioEndpoint. “The value is clear. Working with consultants that have been in the middle manager’s shoes translates to improved efficiency, quality and turnaround in an environment where managers can otherwise struggle against the blistering pace.”

“BioEndpoint will be focused on helping commercial teams get not only the answers they need, but do so in a cost effective fashion,” said Matt Ruple, co-Managing Partner, BioEndpoint Consulting. “It is about delivering accurate, value-driving results and delivering them with the bottom line top-of-mind.”

The Managing Partners at BioEndpoint Consulting each have 15-25 years experience in the industry. The team offers its clients firsthand experience and support in the following areas: marketplace evaluation and competitive intelligence; managed care and pricing strategy; clinical development planning- PI through PIV; product distribution planning; regulatory strategy & REMS development; manufacturing and technical operations planning, commercial launch planning; business development assessment; product sales projections; market research; merger and asset acquisition negotiation and deal structuring

Comments

Search RSS

All rights reserved."